|
|
|
| Surveillance of adverse events following immunization with human papillomavirus vaccines in Hangzhou City from 2017 to 2021 |
| JIANG Wei, LIU Yan, DU Jian, XU Yuyang, CHE Xinren, WANG Jing, WANG Jun, ZHANG Xuechao, GU Wenwen, ZHANG Xiaoping
|
| Department of Immunization Program, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang 310021, China |
|
|
|
|
Abstract Objective To investigate the incidence of adverse events following immunization (AEFI) of human papillomavirus (HPV) vaccines in Hangzhou City from 2017 to 2021, so as to provide insights into safety monitoring and evaluation for HPV vaccines. Methods The AEFI caused by immunization of bivalent (HPV2), quadrivalent (HPV4) and nonavalent HPV vaccines (HPV9) reported in Hangzhou City from 2017 to 2021 were captured from the AEFI Surveillance Module of Chinese Disease Control and Prevention Information System, and HPV vaccination data were captured from the Zhejiang Municipal Immunization Information Management System. The incidence, temporal distributions and clinical symptoms of AEFI were analyzed. Results Totally 922 310 doses of HPV vaccines were immunized in Hangzhou City from 2017 to 2021, and 232 cases with AEFI were reported, with an overall incidence rate of 25.15/105 doses. The reported incidence rates of AEFI caused by HPV2, HPV4 and HPV9 vaccination were 31.13/105 doses, 25.93/105 doses and 22.01/105 doses, respectively. General reactions and abnormal reactions were predominant AEFI, and the reported incidence rates of general reactions and abnormal reactions were 21.58/105 doses and 2.60/105 dose, respectively. AEFI predominantly occurred 0 to 1 day post-immunization (165 cases, 71.12%), and the main clinical symptoms included local swelling of injection sites, hard tubercle and fever, with reported incidence rates of 10.30/105 doses, 5.96/105 doses and 6.18/105 doses, respectively. Conclusions Low incidence of AEFI was reported following HPV vaccination in Hangzhou City from 2017 to 2021, and all AEFI were mild. The safety of HPV2, HPV4 and HPV9 remains high.
|
|
Received: 19 September 2022
Revised: 02 November 2022
Published: 11 January 2023
|
|
|
|
|
|
[1] CHESSON H W,DUNNE E F,HARIRI S,et al.The estimated lifetime probability of acquiring human papillomavirus in the United States[J].Sex Transm Dis,2014,41(11):660-664.
[2] 金孔军,周悦,葛学娣.大学生人群HPV疫苗认知及影响因素研究进展[J].预防医学,2019,31(5): 470-473.
[3] HILDESHEIM A,WACHOLDER S,CATTEAU G,et al.Efficacy of the HPV-16/18 vaccine:Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial[J].Vaccine,2014,32(39):5087-5097.
[4] KJAER S K,SIGURDSSON K,IVERSEN O E,et al.A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus(Types 6/11/16/18)vaccine against high-grade cervical and external genital lesions[J].Cancer Prev Res,2009,2(10):868-878.
[5] JOURA E A,GIULIANO A R,IVERSEN O E,et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J].N Engl J Med,2015,372(8):711-723.
[6] 杨旭梅,金蓉蓉,周慧玲,等.HPV疫苗研究进展及推广接种过程中的影响因素[J].中华临床医师杂志:电子版,2021,15(3)218-223.
[7] 中华人民共和国卫生部办公厅,国家食品药品监督管理局办公室.全国疑似预防接种异常反应监测方案[Z].2010.
[8] 张丽娜,李克莉,杜雯,等.2018年中国疑似预防接种异常反应监测[J].中国疫苗和免疫,2020,26(4):363-375.
[9] 孙肖瑜,魏晶娇,郑晓春,等.2018—2019年温州市女性人乳头瘤病毒疫苗疑似预防接种异常反应监测[J].中国疫苗和免疫,2020,26(4):376-378.
[10] World Health Organization.Human papillomavirus vaccines:WHO position paper,May 2017-Recommendations[J].Vaccine,2017,35(43):5753-5755.
[11] COSTA A P F,COBUCCI R N O,DA SILVA J M,et al.Safety of human papillomavirus 9-valent vaccine:a meta-analysis of randomized trials [J/OL].J Immunol Res,2017[2022-11-02].http://doi.org/10.1155/2017/3736201
[12] VILLA A,PATTON L L,GIULIANO A R,et al.Summary of the evidence on the safety,efficacy,and effectiveness of human papillomavirus vaccines:umbrella review of systematic reviews[J].J Am Dent Assoc,2020,151(4):245-254.
[13] 刘捷宸,吴琳琳,白庆瑞,等.上海市2017—2019年人乳头瘤病毒疫苗接种率和疑似预防接种异常反应监测[J].中国疫苗和免疫,2021,26(3):322-325. |
|
|
|
